A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries

Purpose/aim of the study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries. Materials and methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days. Disease control, itching/pruritus, and patient satisfaction were assessed using Scoring Atopic Dermatitis (SCORAD), AD Control Tool (ADCT), and Patient Global Assessment of Treatment Effect (PGATE) scores at weeks 4, 12, and 24. Results: The study included 187 participants with a mean age of 33.6 years. After 24 weeks, 75.1% of patients achieved disease control (ADCT score <7) compared to 4.3% at baseline (p < 0.001). Both ADCT and SCORAD scores significantly decreased from baseline scores (from 16.5 to 4.1 and 57.5 to 13.4, respectively, p < 0.001). Also, patient satisfaction improved significantly, with 65.3% reporting “Very Good” or “Excellent” PGATE scores in the 24th week compared to 20.3% at the baseline (p < 0.001). The limitations are the small number of included patients and the lack of long-term safety data. Conclusion: In conclusion, Dupilumab therapy is effective in controlling symptoms of moderate-to-severe AD patients in the Gulf countries. Most patients achieved high disease control and satisfaction levels.